Drugs in Dev. Endocrinology
Phase I
France 
Lead Product(s) : AZP-3813
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : PeptiDream
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZP-3813, a peptide GHR antagonist, is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogues (SSAs) for patients who do not adequately respond to SSAs alone.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 05, 2023
Lead Product(s) : AZP-3813
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : PeptiDream
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
Details : AZP-3601, a long-acting parathyroid hormone (PTH) analog, normalizes blood calcium in thyroparathyroidectomized (TPTX) rats without causing deleterious changes in bone.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Tonghua Dongbao Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 13, 2022
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Tonghua Dongbao Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Tonghua Dongbao Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 13, 2022
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Tonghua Dongbao Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZP-3601, investigational therapeutic peptide designed to target specific conformation of PTH receptor safely produce sustained and stable levels of calcium in blood and manage symptoms of hypoparathyroidism, with goal of consequently preventing chronic ...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 17, 2022
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyro...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 01, 2022
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALF-5755
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : T.H.A.C.
Deal Size : Undisclosed
Deal Type : Acquisition
Details : This acquisition strengthens the protection and the potential of the First in Class drug candidate of T.H.A.C which incorporates the active ingredient ALF-5755 for the treatment of Type 2 Diabetes Mellitus and severe complications.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
September 27, 2021
Lead Product(s) : ALF-5755
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : T.H.A.C.
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Sectoral Asset Management
Deal Size : $80.0 million
Deal Type : Series B Financing
Details : Amolyt will use the proceeds to advance its pipeline for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 16, 2021
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Sectoral Asset Management
Deal Size : $80.0 million
Deal Type : Series B Financing
Lead Product(s) : Insulin Lispro,Pramlintide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
Details : Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.
Product Name : BC LisPram
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 29, 2021
Lead Product(s) : Insulin Lispro,Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from all cohorts from its Phase 1 Single Ascending Dose clinical trial evaluating AZP-3601, a parathyroid hormone (PTH) analog specifically designed for the treatment of hypoparathyroidism will be presented.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 18, 2021
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
